Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development
Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development
BALTIMORE and IRVINE, Calif., April 13, 2023 /PRNewswire/ -- Sysmex Inostics Inc., a subsidiary of Japan's Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative (GTC), based in Irvine, California, formed a strategic partnership for Sysmex Inostics to commercialize GTC's tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers. This includes GTC's Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services.
巴尔的摩 和 加利福尼亚州尔湾市， 2023年4月13日 /PRNewswire/ — Sysmex Inostics Inc.，其子公司 日本的 Sysmex 公司和 巴尔的摩总部位于生物技术公司和基因组测试合作社（GTC），总部设在 加利福尼亚州欧文，与Sysmex Inostics建立了战略合作伙伴关系，向生物制药客户商业化GTC的组织和液体活检实体瘤和血液学检测服务。这包括GTC的实体瘤Profile Profile Plus、Liquid trace Hemology Profile Plus、Liquid trace Hemoto
The partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics's global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.
该合作伙伴关系将GTC的专有基因组数据库、人工智能（AI）技术以及DNA和RNA下一代测序（NGS）分析与Sysmex Inostics在生物制药治疗开发方面的全球商业能力和超灵敏的Plasma-safe-seqs技术相结合。
Shinichi Sato, president, and Chief Executive Officer of Sysmex Inostics, stated, "Our new relationship with GTC extends our commitment to our biopharma partners. We understand not one testing solution fits all stages of therapeutic development and it was imperative to offer our biopharma partners GTC's broader panels for their discovery work." And added, "It's truly a special day for Sysmex Inostics."
佐藤真一，Sysmex Inostics总裁兼首席执行官表示：“我们与GTC的新关系扩大了我们对生物制药合作伙伴的承诺。我们知道没有一种测试解决方案适合治疗开发的所有阶段，因此必须为我们的生物制药合作伙伴GTC的发现工作提供更广泛的试剂盒。”并补充说：“对于 Sysmex Inostics 来说，这确实是特别的一天。”
"The alliance with Sysmex Inostics is fundamental to our mission of democratizing genomic testing and making it available and affordable to every patient dealing with cancer. It represents another step forward in our efforts to expand our cooperative model," stated Maher Albitar, MD, Founder, Chief Executive Officer, and Chief Medical Officer of GTC.
“与Sysmex Inostics的联盟对我们的使命至关重要，我们的使命是实现基因组检测的民主化，让每位患癌症的患者都能负担得起基因组检测。这是我们在扩大合作模式方面向前迈出的又一步，” 说 Maher Albitar，医学博士，GTC创始人，首席执行官兼首席医学官。
The collaboration provides biopharma a full suite of assay services from both companies for each phase in the clinical trial process. The companies will also work jointly on improvements and new indications of the tests for use by biopharma researchers.
该合作为生物制药提供了两家公司在临床试验过程的每个阶段提供的全套分析服务。两家公司还将共同研究测试的改进和新的适应症，供生物制药研究人员使用。
GTC's cooperative state-of-the-art and cost-effective offerings are distinctive and cover various modalities including chromosomal abnormalities, RNA expression and immunophenotyping, tumor cell of origin, homologous recombination deficiency (HRD), tumor mutation burden (TMB), exon skipping, and levels of EBV and HPV viral RNA if present. GTC testing uses proprietary AI analysis of DNA and RNA data from blood and tissue samples. Further setting them apart, various GTC's tests have CE IVDR and New York State (NYS) approval with Medicare Reimbursement, the lab has CAP, CLIA and NYS licensure.
GTC 最先进且具有成本效益的合作产品与众不同，涵盖各种模式，包括染色体异常、RNA 表达和免疫分型、肿瘤起源、同源重组缺陷 (HRD)、肿瘤突变负担 (TMB)、外显子跳跃以及 EBV 和 HPV 病毒 RNA 水平（如果存在）。GTC 测试使用专有的人工智能分析来自血液和组织样本的 DNA 和 RNA 数据。更让他们与众不同的是，GTC 的各种测试都有 CE IVDR 和 纽约州 （纽约州）批准了医疗保险报销计划，该实验室拥有CAP、CLIA和纽约州许可证。
Sysmex Inostics adds its long-standing biopharma relationships and commercial capabilities to the partnership. The company will also continue to serve the market with CLIA-validated Plasma-Safe-SeqS testing, expertly curated and ultra-sensitive liquid biopsy panel to detect known cancer driving mutations. The technology allows biopharma to expedite clinical trial patient enrollment with the peace of mind their patients are being monitored with one of the most sensitive liquid biopsy tests on the market.
Sysmex Inostics为合作伙伴关系增加了其长期的生物制药关系和商业能力。该公司还将继续为市场提供经CLIA验证的Plasma-safe-seqs测试、经过专业策划的超灵敏液体活检小组，以检测已知的癌症驱动突变。该技术使生物制药公司能够加快临床试验患者的入组，高枕无忧，他们的患者正在接受市场上最敏感的液体活检测试之一的监测。
Sysmex Inostics & GTC will exhibit at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL from April 16, through April 19, 2023. Both companies will take meetings with the over 20,000 global cancer research professionals in attendance.
Sysmex Inostics 和 GTC 将在 2023 年美国癌症研究协会 (AACR) 年会上展出 佛罗里达州奥兰多 从 4 月 16 日，通过 2023年4月19日。两家公司都将与出席会议的20,000多名全球癌症研究专业人员举行会议。
About Sysmex Inostics
关于 Sysmex Inostics
Sysmex Inostics, Inc., a subsidiary of Japan's Sysmex Corporation, is a Baltimore-based biotechnology firm and CLIA-certified lab offering biomarker testing to accelerate the development of personalized medicine.
Sysmex Inostics, Inc.，其子公司 日本的 Sysmex 公司是 巴尔的摩总部位于生物技术公司和CLIA认证的实验室，提供生物标志物测试，以加速个性化医疗的开发。
The company's goal is to transform the future of health, so life's potential is not determined by a diagnosis of cancer and other devasting diseases. Utilizing its patented technologies, Sysmex Inostics can detect rare and minute traces of some of the world's most elusive diseases, allowing for actionable insights to treat patients most effectively and enable them to live their fullest life beyond diagnosis.
该公司的目标是改变健康的未来，因此生命的潜力不是由癌症和其他毁灭性疾病的诊断决定的。利用其专利技术，Sysmex Inostics可以检测出世界上一些最难以捉摸的疾病的罕见微小痕迹，从而提供切实可行的见解，以最有效地治疗患者，使他们能够在诊断后过上最充实的生活。
Since 2008, Sysmex Inostics has played a significant role in solid tumor and liquid cancer discoveries serving the pharmaceutical, clinical, and research communities with the first commercially available liquid biopsy technology, OncoBEAM. Now with its next generation sequencing (NGS) Plasma-Safe-SeqS technology panels, Sysmex Inostics empowers more accurate detection of low-frequency biomarkers with ultra-sensitive 0.03% to 0.05% allele frequency from a simple blood draw to expedite studies and uncover deeper insights into therapy response.
自 2008 年以来，Sysmex Inostics 在实体瘤和液体癌的发现中发挥了重要作用，为制药、临床和研究界提供首个市售液体活检技术 OncoBeam。现在，借助其下一代测序 (NGS) Plasma-safe-seqs 技术面板，Sysmex Inostics 可以更准确地检测出通过简单抽血获得的超灵敏度为 0.03% 至 0.05% 等位基因频率的低频生物标志物，从而加快研究并揭示对治疗反应的更深入见解。
The company offers CLIA validated NGS testing services for AML, breast cancer, HPV16/18 quantification, HNSCC, and solid tumors impacted by RAS-RAF and PI3K signaling pathways.
该公司为受RAS-RAF和PI3K信号通路影响的急性髓细胞白血病、乳腺癌、HPV16/18定量、HNSCC和实体瘤提供经CLIA验证的NGS测试服务。
In 2021, Sysmex Corporation announced a global strategic alliance with QIAGEN to provide custom cancer companion diagnostics (CDx) utilizing Plasma-Safe-SeqS technology. The alliance is intended to promote early clinical implementation of Sysmex Inostics' technology to expedite clinical trial timelines for pharmaceutical companies that develop molecularly targeted drugs for cancer.
2021 年，Sysmex 公司宣布与 QIAGEN 建立全球战略联盟，使用 Plasma-safe-seqs 技术提供定制癌症伴随诊断 (CDx)。该联盟旨在促进Sysmex Inostics技术的早期临床实施，以加快开发癌症分子靶向药物的制药公司的临床试验时间表。
About Genomic Testing Cooperative, LCA
关于基因组测试合作社，LCA
Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. The company operates based on a cooperative (co-op) business model. Members of the co-op hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit
基因组测试合作社（GTC）是一家私营分子测试公司，位于 加利福尼亚州尔湾 该公司基于合作（合作社）的商业模式运营。合作社成员持有具有投票权的A类股票。该公司主要基于下一代测序，为其赞助成员提供一整套全面的基因组分析。合作模式允许GTC以较低的成本向成员提供测试和信息平台，因为管理费用较低。欲了解更多信息，请访问
SOURCE Sysmex Inostics
来源 Sysmex Inostics